Financials

  • Market Capitalization 963.91 M
  • Employee 81
  • Founded 1995
  • CEO Lonnel Coats
  • Website www.lexpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ85G2
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-8.21
Price to sales ratio
8.38

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2494
KURA
Kura Oncology, Inc. - Common Stock
10.91 USD-4.72%-2.76%+18.85%+70.74%968.53 M USD
2497
PHAR
Pharming Group N.V. - ADS, each representing 10
13.75 USD+0.22%-4.71%+4.56%+31.96%964.81 M USD
2506
SLDB
Solid Biosciences Inc. - Common Stock
9.72 USD-6.72%-12.20%+33.70%+70.53%956.93 M USD
2510
DBVT
DBV Technologies S.A. - American Depositary Shares
15.98 USD-3.09%-0.44%-9.62%+53.21%946.15 M USD

Frequently asked questions about Lexicon Pharmaceuticals, Inc. - Common Stock

What is the Lexicon Pharmaceuticals, Inc. - Common Stock stock price today?

The current price of Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX) is 2.17. Over the past 24 hours, the stock has changed by -2.25%. Follow the LXRX chart for real-time price dynamics.

What is the stock ticker of Lexicon Pharmaceuticals, Inc. - Common Stock?

Lexicon Pharmaceuticals, Inc. - Common Stock trades under the ticker LXRX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Lexicon Pharmaceuticals, Inc. - Common Stock stock going up?

LXRX has changed by -6.47% over the last week, +11.28% over the last month, and +82.35% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Lexicon Pharmaceuticals, Inc. - Common Stock net income for the last quarter?

Lexicon Pharmaceuticals, Inc. - Common Stock reported net income of -1.04 M for the last quarter. The previous quarter showed -15.53 M, which means net income changed by +93.28%.

How many employees does Lexicon Pharmaceuticals, Inc. - Common Stock have?

As of the latest available data, Lexicon Pharmaceuticals, Inc. - Common Stock has 81 employees. Workforce size can provide additional context about the company's scale and operations.

What is Lexicon Pharmaceuticals, Inc. - Common Stock EBITDA?

Lexicon Pharmaceuticals, Inc. - Common Stock EBITDA is -886 K, and its EBITDA margin is -4.2%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Lexicon Pharmaceuticals, Inc. - Common Stock stock?

You can buy Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Lexicon Pharmaceuticals, Inc. - Common Stock stock?

Investing in Lexicon Pharmaceuticals, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the LXRX chart and related analysis on metatrader.com as part of your research.

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

News